Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ISAL 2019 | Investigating relapse after allo-SCT in AML

The cause of relapse in acute myeloid leukemia (AML) following allogeneic stem cell transplant is unknown, with many theories under investigation. John DiPersio, MD, PhD, of Washington University School of Medicine, Washington, WA, discusses our current understanding of this event from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany, with a major focus on CT2A.